Post‑Exposure Management of HSV‑2: Evidence‑Based Recommendations

1. Lack of Evidence for Antiviral Post‑Exposure Prophylaxis

The 2022 CDC sexually transmitted infection treatment guidelines state that there are no data supporting the use of acyclovir, famciclovir, or valacyclovir as post‑exposure prophylaxis to prevent HSV‑2 acquisition in HSV‑2‑negative individuals. Evidence level: none. 1, 2, 3, 4, 5
Consequently, the CDC advises against prescribing any of these antivirals (acyclovir, valacyclovir, famciclovir) for post‑exposure prophylaxis, as doing so is not evidence‑based and may give false reassurance. Evidence level: none. 1, 2, 3

Baseline type‑specific HSV‑2 serology should be obtained immediately after exposure to document pre‑exposure status, followed by repeat testing at 3–4 months to detect seroconversion. Evidence level: CDC recommendation. 6
Antibody detection may be delayed up to 12 weeks, and early testing can yield false‑negative results; clinicians must counsel patients about this limitation. Evidence level: CDC. 6

Daily tenofovir disoproxil fumarate (TDF) reduced HSV‑2 seroconversion by ~30 % in HIV‑negative, HSV‑2‑negative heterosexual discordant couples in African studies. Evidence level: observational cohort. 1, 2, 3, 4, 5
The CDC notes insufficient evidence to recommend TDF/FTC for HSV‑2 prevention in individuals not at risk for HIV, and it should not be used solely for this purpose. Evidence level: CDC. 1, 2, 3, 4, 5
In men who have sex with men (MSM), on‑demand TDF/FTC PrEP did not decrease HSV‑2 acquisition risk. Evidence level: randomized trial. 1, 2, 3, 4, 5

The USPSTF recommends against routine HSV‑2 screening in asymptomatic persons with low pre‑test probability (few lifetime partners, no known HSV‑2‑positive partner, no genital symptoms). Evidence level: strong recommendation. 6
Serologic screening is appropriate for persons with increased epidemiologic risk, including:

Emphasize pre‑exposure prevention (partner suppressive therapy, consistent condom use, avoidance of sexual contact during visible lesions) rather than post‑exposure antiviral prophylaxis, which lacks supporting evidence. Evidence level: CDC. 1
After a known exposure, monitor for symptoms and conduct serial serologic testing (baseline and 3–4 months) to identify possible seroconversion. Evidence level: CDC. 1

The Centers for Disease Control and Prevention (CDC) recommends consistent latex condom use during every act of sexual intercourse to reduce HSV-2 acquisition from women to men and from men to women 7
The CDC advises avoiding sexual contact when partners have overt genital or orolabial herpetic lesions, as this is the highest-risk period for transmission 7, 8
Requesting type-specific serologic testing of partners before initiating sexual activity can help reduce transmission risk, as disclosure of HSV-2 status in heterosexual HSV-2-discordant couples was associated with reduced transmission risk 7
The CDC suggests that suppressive antiviral therapy in the infected partner (valacyclovir 500 mg once daily) can reduce HSV-2 transmission to susceptible heterosexual partners by 50% 7

The CDC states that sexual transmission of HSV can occur during asymptomatic viral shedding, even when no visible lesions are present 7
If exposure has already occurred or is imminent and unavoidable, the focus should be on monitoring for symptoms of primary HSV-2 infection (painful genital ulcers, systemic symptoms, lymphadenopathy) 7
The CDC recommends seeking immediate evaluation if symptoms develop, as first-episode genital herpes should be treated with antiviral therapy for 7-10 days 9, 10
Type-specific serologic testing at baseline and 3-4 months post-exposure can help determine if infection occurred 7